|
(ÁÖ)·òµåÄÚ¸®¾Æ |
¿Ü±¹°è ¹ÙÀÌ¿À¸ÞµðÄà CRA,CROä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
08.20 |
|
|
´õÁ¸Àâ |
¿Ü±¹°èÀÇ·á±âȸ»ç-¿µ¾÷ºÎMR(¼øȯ±â)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Advisor/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
2³â¡è |
ä¿ë½Ã |
11.02 |
|
|
(ÁÖ)ÄھƼġ |
oncology marketing
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
10³â¡è |
ä¿ë½Ã |
11.14 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
JPM(OTCÁ¦Ç°)/±¹³»majorÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
08.03 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Sr. CRA & CRA/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
ä¿ë½Ã |
09.21 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
ÀÇ·á±â ÀÇ·áÁ¦Ç° º´¿ø¿µ¾÷´ã´ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
10.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(Oncology)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
1³â¡è |
ä¿ë½Ã |
11.02 |
|
|
Æ®·¯½ºÆ®ºê¸´Áö |
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
½ÅÀÔ |
ä¿ë½Ã |
10.26 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
QA Manager/¿Ü±¹°èÇÕÀÛÁ¦¾àȸ»ç
°æ±â ±ºÆ÷½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
12.31 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Ç°Áú¿î¿µ½ÇÀå(ÀÓ¿ø±Þ)/±¹³»majorÁ¦¾àȸ»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
10³â¡è |
ä¿ë½Ã |
12.01 |
|
|
K1partners |
Á¦¾à. ¹ÙÀÌ¿À °³¹ßºÎ¹®(RA, Global, BD, PV, MD, MA, Licens
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.17 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
´ç´¢ÆÀ MSL Manager/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
5³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(Cardio Vascular)/¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
1³â¡è |
ä¿ë½Ã |
08.03 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
RA ÆÀÀå(Â÷ºÎÀå±Þ)/¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
01.13 |
|